The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The safety and efficacy of elotuzumab for the treatment of multiple myeloma
In this video, Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some insights into the safety and efficacy of elotuzumab for the treatment of multiple myeloma, drawing focus on updated results from the SWOG-1211 trial (NCT01668719). Dr Richardson comments on the encouraging survival data observed with the addition of elotuzumab to bortezomib, lenalidomide and dexamethasone (RVd), and further emphasizes the tolerability of this combination. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
